高级搜索
血液及痰液miRNAs检测在肺癌早期筛查和诊断中的价值[J]. 肿瘤防治研究, 2015, 42(06): 627-630. DOI: 10.3971/j.issn.1000-8578.2015.06.021
引用本文: 血液及痰液miRNAs检测在肺癌早期筛查和诊断中的价值[J]. 肿瘤防治研究, 2015, 42(06): 627-630. DOI: 10.3971/j.issn.1000-8578.2015.06.021
Clinical Value of miRNAs in Blood or Sputum as Biomarkers for Early Screening and Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(06): 627-630. DOI: 10.3971/j.issn.1000-8578.2015.06.021
Citation: Clinical Value of miRNAs in Blood or Sputum as Biomarkers for Early Screening and Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(06): 627-630. DOI: 10.3971/j.issn.1000-8578.2015.06.021

血液及痰液miRNAs检测在肺癌早期筛查和诊断中的价值

Clinical Value of miRNAs in Blood or Sputum as Biomarkers for Early Screening and Diagnosis of Lung Cancer

  • 摘要: 肺癌已经成为了世界上发病率和死亡率增长最快的恶性肿瘤之一。微小RNA(microRNA, miRNA)在血液及痰液中的变化反映了肺癌发生发展的状况。因此血液及痰液中的miRNAs可以作为一种新的肿瘤标志物运用到肺癌的早期筛查和诊断中。本文就miRNAs与肺癌发生发展的关系,以及血液及痰液中miRNAs检测在肺癌早期筛查和诊断中的临床价值进行综述。

     

    Abstract: Lung cancer has become one of the malignant tumors with fastest growing morbidity and highest mortality in the world. Altered expression of microRNAs(miRNAs) in blood and sputum could reflect the development of lung cancer. Therefore, the miRNAs in blood or sputum could be used as new tumor biomarkers and applied to the early screening and diagnosis of lung cancer. This article reviews the roles of miRNAs in the development of lung cancer, and the clinical value of miRNAs in blood and sputum for the early screening and diagnosis of lung cancer.

     

/

返回文章
返回